Michael R. Hodges

Michael R. Hodges

Auto-generated profile, based on publicly available information

Michael R. Hodges

Independent/Former Amplyx Pharmaceuticals Inc , San Diego, California

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2025 in Clinical Infectious Diseases
Verified
Journal Article
Open access
MHMichael R Hodges
Michael R Hodges
MTMargaret Tawadrous
Margaret Tawadrous
OCOliver A. Cornely
Oliver A. Cornely
George ThompsonGeorge Thompson
George Thompson
MSMonica A Slavin
Monica A Slavin
RPRienk Pypstra
Rienk Pypstra
Background: Fosmanogepix (FMGX) inhibits glycosylphosphatidylinositol anchored cell wall transfer protein 1, essential for anchoring mannoproteins to fungal cell wall, critical for host invasion. This Phase 2 study evaluated efficacy and safety of FMGX treatment in invasive mold diseases (IMDs) by Aspergillus spp. and rare molds in adults with limited treatment options. Methods: Participants (≥18 years) received FMGX 1000 mg intravenously (IV; 3-hour infusion) twice on Day 1 followed by 600 mg IV or 800 mg oral (optional from Day 4) once a day for ≤42 days. Key endpoints were all-cause mortality (Day 42) and Data Review Committee (DRC)-assessed global response (end of study treatment), adjudicated as success (complete or partial response) or failure (stable disease or progression of disease or death). Results: Of 21 participants enrolled (safety population), 20 were included in the modified Intent-to-Treat population (mean age: 61.9 years; females: 2 [10%]). Day-42 all-cause mortality was 25% (80% confidence interval [CI]: 12.7%—41.5%). DRC-assessed global response success rate was 40% (80% CI: 24.9%—56.7%). 258 adverse events (AEs) were reported (n = 21). 15 participants experienced 36 FMGX-related AEs, 2 had 3 serious AEs. Three participants (14.3%) discontinued study treatment due to FMGX-related AEs. Nine deaths (43%) were reported. One death was assessed as possibly related and unrelated to FMGX by the investigator and Data and Safety Monitoring Board, respectively. Conclusions: Safety profile was acceptable in high-risk patients with limited treatment options, supporting development of FMGX for treating IMDs caused by Aspergillus and rare molds. Clinical Trials Registration. NCT04240886; EudraCT number: 2019-001386-33.

10 July 2024 in American Journal of Transplantation
Verified
Journal Article
Open access
JAJohanna R. Abend
Johanna R. Abend
ASAtul Sathe
Atul Sathe
MWMatthias B. Wrobel
Matthias B. Wrobel
MKMark Knapp
Mark Knapp
LXLucy Xu
Lucy Xu
SKSteven J. Kovacs
Steven J. Kovacs
Reactivation of BK polyomavirus (BKPyV) can cause significant kidney and bladder disease in immunocompromised patients. There are currently no effective, BKPyV-specific therapies. MAU868 is a novel, human IgG1 monoclonal antibody that binds the major capsid protein VP1 of BKPyV with picomolar affinity, neutralizes infection by the four major BKPyV genotypes (EC50 ranging from 0.009 to 0.093 μg/ml; EC90 ranging from 0.102 to 4.160 μg/ml), and has comparable activity against variants with highly prevalent VP1 polymorphisms. No resistance-associated variants were identified in long-term selection studies, indicating a high in vitro barrier-to-resistance. The high-resolution crystal structure of MAU868 in complex with VP1 pentamer identified three key contact residues in VP1 (Y169, R170, K172). A first-in-human study was conducted to assess the safety, tolerability, and pharmacokinetics of MAU868 following intravenous and subcutaneous administration to healthy adults in a randomized, placebo-controlled, double-blinded, single ascending dose design. MAU868 was safe and well-tolerated. All adverse events were Grade 1 and resolved. The pharmacokinetics of MAU868 was typical of a human IgG, with dose-proportional systemic exposure and an elimination half-life ranging between 23 and 30 days. These results demonstrate the potential of MAU868 as a first-in-class therapeutic agent for the treatment or prevention of BKPyV disease.

1 April 2012 in Journal of Hepatology
Verified
Journal Article
Closed access
APA.K. Patick
A.K. Patick
ACA. Chen
A. Chen
LDL.J. van Doorn
L.J. van Doorn
EVE. van der Veer
E. van der Veer
KZK. Zeh
K. Zeh
MHM.R. Hodges
M.R. Hodges